DAVID BARNEY: Open Payments
NPI 1437254430 · GRAND RAPIDS, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,425 in 275 payments from 25 companies in 2025. Trend: 2023 $3,876 · 2024 $4,351 · 2025 $4,425
Food & beverage: $4,425
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 33 | $608 |
| ABBVIE INC. | 43 | $580 |
| Lilly USA, LLC | 17 | $349 |
| Otsuka America Pharmaceutical, Inc. | 22 | $312 |
| PFIZER INC. | 20 | $301 |
| AstraZeneca Pharmaceuticals LP | 13 | $261 |
| Neurocrine BioSciences, Inc. | 11 | $252 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 13 | $213 |
| Currax Pharmaceuticals LLC | 16 | $191 |
| GlaxoSmithKline, LLC. | 12 | $174 |
Products named: REXULTI, VRAYLAR, MOUNJARO, Wegovy, INGREZZA, Ozempic, AIRSUPRA, UBRELVY.
Industry payments across MI — which companies pay providers there.
